Asalyxa Bio Closes Seed Financing to Advance Lead Program into First-in-Human Clinical Studies

By PR Newswire4 days ago

ANN ARBOR, Mich., Feb. 23, 2021 /PRNewswire/ -- Asalyxa Bio, Inc., a biopharmaceutical company developing nano-engineered, immune cell-targeted therapeutics, today announced the closing of an over-subscribed seed financing round totaling more than $2 million. The financing was led by...

Continue read on prnewswire.com